Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors
Andrea M. Zuhl(Pfizer (United States)), Douglas S. Johnson(Biogen (United States)), David Riddell(Eli Lilly (United States)), Christopher Houle(Pfizer (United States)), Christopher W. am Ende(Pfizer (United States)), Xinjun Hou(Pfizer (United States)), Kieran F. Geoghegan(Pfizer (United States)), David A. Karanian(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), Joshua C. Judkins(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sherry Niessen(Pfizer (United States)), Jeffrey W. Brulet(Pfizer (United States)), Cheng Chang(National University of Singapore), Brian T. O’Neill(Pfizer (United States)), Graham M. West(Scripps Research Institute), Elizabeth M. Beck(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 77
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector
|Cell|2004|660
Bioorthogonal chemistry
|Nature Reviews Methods Primers|2021|554
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460